Exposure time versus cytotoxicity for anticancer agents.
David M EvansJianwen FangThomas SilversRene DeloshJulie LaudemanChad OgleRussell ReinhartMichael SelbyLori BowlesJohn ConnellyErik HarrisJulia KrushkalLarry RubinsteinJames H DoroshowBeverly A TeicherPublished in: Cancer chemotherapy and pharmacology (2019)
The results suggest that variations in compound exposure time may reflect either mechanism of action or compound chemical half-life. The activity of slow-acting compounds may optimally be assessed in spheroid models that can be monitored over prolonged incubation times.
Keyphrases